You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

624 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Drug
Other Name(s): Polivy™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PERTuzumab / trastuzumab (subcut) (Unfunded),
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PERTuzumab / trastuzumab (subcut) (Unfunded),
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PERTuzumab / trastuzumab (subcut) (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2022
Guidelines and Advice
Status: Current
ID: PET 2021-2
Jun 2022
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pemigatinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022
Drug
Other Name(s): Rozlytrek®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024
Document
Nov 2022
Document
Nov 2022
Statistical Reports
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
PANitumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024

Pages